European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours – a single centre experience","authors":"Raghava Kashyap, Ramin Alipour, Emma Boehm, Kerry Jewell, Aravind S. RaviKumar, Anthony Cardin, Javad Saghebi, Michael S. Hofman, Michael T. Fahey, Michael Michael, Tim Akhurst, Rodney J. Hicks, Grace Kong","doi":"10.1007/s00259-025-07235-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07235-w","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Aim</h3><p>Patients with gastro-entero-pancreatic neuroendocrine tumours (GEP NET) who retain somatostatin receptor (SSTR) expression after initial response to [¹⁷⁷Lu]Lu-DOTA-Octreotate (LuTate) peptide receptor radionuclide therapy (PRRT) are amenable to re-treatment (R-PRRT) upon progression. We assessed the safety and efficacy of R-PRRT in patients with progressive metastatic GEP NET.</p><h3 data-test=\"abstract-sub-heading\">Materials and methods</h3><p>A retrospective analysis, approved by institutional ethics board, was performed in patients with GEP NET who received R-PRRT for either symptomatically or radiologically progressive disease. Safety was assessed by renal and haematological parameters at 3 months post R-PRRT (CTCAE v5.0). Molecular imaging response was evaluated on [⁶⁸Ga]Ga-DOTA-Octreotate (GaTate) PET/CT using pre-defined criteria. RECIST 1.1 responses 3 months post R-PRRT were documented when feasible. Progression-free and overall survival analysis were performed.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>A total of 63 patients had R1-PRRT (1–3 cycles). The majority (70%) had Grade 2 NET and small intestinal primary (51%). A second re-treatment course (R2-PRRT) was given in 20 patients and a third course (R3-PRRT) in 6 patients. Glomerular filtration rate (GFR) was stable following R1-PRRT. Following R2-PRRT, worsening GFR from CTCAE G2 to G3 was seen in 10% (2/20) of patients, but none after R3-PRRT. Grade 3 thrombocytopenia occurred in 2 patients after R1-PRRT and in 1 patient after R3-PRRT. Grade 4 thrombocytopenia was observed in 1 patient post R1-PRRT. Following R1-PRRT, RECIST 1.1 responses CR, PR, SD was 0%, 10%, 76%, respectively. Disease control rate on GaTate PET/CT was 52/58 (89%) post R1-PRRT. Median progression free survival (PFS) following R1-PRRT was 1.6 years (95% CI:1.2–2.3).</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>R-PRRT is feasible, tolerable and efficacious in achieving disease control in patients with progressive GEP NET.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"61 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143702982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-related changes of human brain metabolism","authors":"Shufang Qian, Yihan Ba, Le Xue, Chentao Jin, Rui Zhou, Yi Liao, Yan Zhong, Yuanfan Xu, Feng Shi, Chengyan Wang, Xiaofeng Dou, Yidan Gao, Han Jiang, Peili Cen, Chenchen Lin, Jing Wang, Chuantao Zuo, Jun Zhang, Dinggang Shen, Hong Zhang, Mei Tian","doi":"10.1007/s00259-025-07211-4","DOIUrl":"https://doi.org/10.1007/s00259-025-07211-4","url":null,"abstract":"&lt;h3 data-test=\"abstract-sub-heading\"&gt;Purpose&lt;/h3&gt;&lt;p&gt;Glucose is the primary source of human brain energy, and is closely related to brain function. This study aims to evaluate in vivo glucose metabolic changes using &lt;sup&gt;18&lt;/sup&gt;F-fluorodeoxyglucose positron emission tomography (&lt;sup&gt;18&lt;/sup&gt;F-FDG PET).&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Methods&lt;/h3&gt;&lt;p&gt;In this retrospective analysis, a total of 3,291 healthy adults (aged 18 to 89 years, 1816 males) who underwent &lt;sup&gt;18&lt;/sup&gt;F-FDG PET were recruited (&lt;i&gt;chictr.org.cn ChiCTR2400081809&lt;/i&gt;). Group comparison and brain chart modeling are integrated to examine these changes. Qualitative voxel-wise group comparison among different age and gender groups are analyzed. Brain chart modeling is used to quantitatively estimate aging trajectories, generate predicted values and calculate derived percentage change. Additional analyses of aging peaks and variability are then performed on derived reference values.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Results&lt;/h3&gt;&lt;p&gt;Age-related, gender-specific patterns of glucose metabolic changes are revealed, especially in the frontal, occipital, temporal and parietal lobes. A significantly decrease in metabolism is observed in males aged 45 to 70 compared to females. Metabolic aging trajectories and centile scores demonstrate a gradual decline across the total cortical, subcortical and most brain regions. Additionally, brain regions with maximum values (not at age 18), extreme age points, and their corresponding ages were identified. Specifically, only 12 brain regions exhibited values higher than those at age 18, and only 8 regions displayed extreme points throughout the aging process.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Conclusion&lt;/h3&gt;&lt;p&gt;In summary, our large population study identifies a distinct pattern of brain glucose metabolism during aging that varies between men and women, with two critical age periods based on gender: 45–49, and 70–75. We establish benchmark trajectories for various brain regions, which could serve as references in future aging studies of healthy populations. The aging peaks, including maximum and extreme points, revealed in this study may provide insight into the molecular transformations associated with aging and the development of age-related conditions.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Significance statement&lt;/h3&gt;&lt;p&gt;A number of brain aging changes throughout the lifespan have been well documented, such as reductions in cerebral blood flow, cortical thickness, synaptic density, and neural activity. However, the spatiotemporal patterns of brain functional changes during normal aging remain poorly understood. In this study, we utilized the largest cohort of healthy individuals’ FDG brain images to date. For the first time, we combined qualitative and quantitative metabolic aging analyses, and applied brain chart modeling to &lt;sup&gt;18&lt;/sup&gt;F-FDG PET imaging. By establishing benchmark trajectories for various brain regions, we identifi","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"2 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143702983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study","authors":"Lena M. Unterrainer, Andrea Farolfi, Tristan Grogan, Masatoshi Hotta, Loïc Djaileb, Andrei Gafita, Ida Sonni, Matthew B. Rettig, Florian Rosar, Samer Ezziddin, Chloé S. Denis, Ivan de Kouchkovsky, Rahul Aggarwal, Louise Emmett, Thomas A. Hope, Johannes Czernin, Jeremie Calais","doi":"10.1007/s00259-025-07178-2","DOIUrl":"https://doi.org/10.1007/s00259-025-07178-2","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>An increase of PSMA expression under androgen receptor signaling inhibitors (ARSi) measured on PSMA PET was reported: However, results were inconsistently reproduced clinically and the frequency and timing of the PSMA expression modulation by ARSi remains unknown.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>In this multicenter retrospective study, we aimed at assessing in patients with CRPC the influence of ARSi early after initiation (≤ 30 days) on PSMA expression at the whole-body (WB) level by using WB PSMA PET quantitative parameters. (m)CRPC patients from 5 international sites who underwent a PSMA PET prior to (PET1) and early (&lt; 30 days) after (PET2) ARSi initiation were included. WB-PSMA PET quantitative parameters (PSMA-positive WB-tumor volume (TV), WB-SUV_max, WB-SUV_mean) and PSA changes between PET1 and PET2 (PSA1/PSA2) were evaluated. Changes of WB-TV / WB-SUVmax/mean between PET1 and PET2 were considered significant if ≥ 30% of increase or decrease.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Fifty-six patients who initiated ARSi treatment were included. 30/56 (53.6%) were treated with an ARSi for the first time, 26/56 (41.1%) were previously treated with another ARSi agent and 29/56 (51.9%) received prior chemotherapy. 10/56 (17.9%) had a significantly increasing PSA of ≥ 25% between PET1 and PET2. 15/56 (27%), 14/56 (25%) and 1/56 (1.8%) patients had a significantly increasing WB-TV, WB-SUV_max or WB SUV_mean of ≥ 30% between PET1 and PET2, respectively. The patients with significant WB-TV increase (<i>n</i> = 15) and with significant WB SUV_max increase (<i>n</i> = 14) did not differ significantly from the ones with stable or decreased WB-TV (<i>n</i> = 41) or WB-SUV_max (<i>n</i> = 42) in their clinical characteristics or their PSA responses.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>In this analysis of patients with early PSMA PET follow-up after ARSi initiation, we observed a PSMA-upregulation by WB-PET imaging in 25% of the patients. Further studies are needed to better understand the potential synergistic and / or additive effects of AR- and PSMA-targeted approaches.</p><h3 data-test=\"abstract-sub-heading\">Clinical trial number</h3><p>Not applicable.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"9 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143703039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Vaz et al., Editorial Commentary: Should \"Heterogeneous response\" be considered as new category for assessing treatment response in patients with breast cancer?","authors":"Renske Altena, Thuy A Tran, Antonios Tzortzakakis","doi":"10.1007/s00259-025-07206-1","DOIUrl":"https://doi.org/10.1007/s00259-025-07206-1","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143700051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition)","authors":"Yan-Song Lin, Ren-Fei Wang, Rui Huang, Qiang Wen, Wei Cao, Li-Bo Chen, Ye Guo, Xiao-Rong Hou, Li Li, Xiao-Yi Li, Cheng-He Lin, Zhi-Yan Liu, Hao Wang, Xu-Fu Wang, Zhuo-Ying Wang, Xiao-Hong Wu, Shu-Hang Xu, Ai-Min Yang, Bo Zhang, Yue-Lun Zhang","doi":"10.1007/s00259-025-07222-1","DOIUrl":"https://doi.org/10.1007/s00259-025-07222-1","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) has become a challenge in clinical practice, particularly in China with a high incidence and undesirable survival outcome. Since the publication of first China consensus on the diagnosis and treatment of RAIR-DTC in 2019, significant and rapid advances have occurred in the field both in China and internationally. This guideline aims to inform Chinese clinicians, researchers, patients, and health policy makers on the latest evidence and recommendations, to further standardize the clinical diagnosis and treatment of RAIR-DTC.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>The structured clinical questions addressed in this guideline were derived from clinical diagnostic and treatment processes, with references to study, prior guidelines, expert consensus, and systematic reviews, etc. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used for quantitative and qualitative evaluation of the evidence. The editorial process was completely independent of the guideline development group.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The guideline addressed 26 clinical questions and formed 35 recommendations. In this guideline, the definition criteria for RAIR-DTC was optimized, prediction and identification was based on evidence including molecular testing, dynamic biochemical changes, and multimodal imaging. Comprehensive pre-treatment clinical evaluation was emphasized and tailored for individualized decision-making. The combination of systematic therapy and surgery, and the redifferentiation followed by RAI therapy were also reviewed and updated. Molecular imaging plays a unique role in the pre-assessing and therapeutic response evaluation for RAIR-DTC.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>We have updated and developed evidence-based recommendations with the aim of providing scientific, rigorous, and comprehensive guidance for the clinical diagnosis and treatment of RAIR-DTC patients in China. We hope to share our guideline with colleagues out of China, with the expectation of further comments and suggestions.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"215 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143695366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute cytotoxic edema after radioembolization of the liver with Y-90 microspheres observed on DWI in post-therapy Y-90 PET/MRI","authors":"Burak Demir, Cigdem Soydal, Emre Can Celebioglu, Mehmet Sadık Bilgic, Digdem Kuru Oz, Nuriye Ozlem Kucuk","doi":"10.1007/s00259-025-07225-y","DOIUrl":"https://doi.org/10.1007/s00259-025-07225-y","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"28 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143695816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Localization of sentinel lymph nodes using augmented-reality system: a cadaveric feasibility study","authors":"Heying Duan, Yue Yang, Wally L. Niu, David Anders, Andrew M. Dreisbach, Dawn Holley, Benjamin L. Franc, Steffi L. Perkins, Christoph Leuze, Bruce L. Daniel, Fred M. Baik","doi":"10.1007/s00259-025-07216-z","DOIUrl":"https://doi.org/10.1007/s00259-025-07216-z","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Sentinel lymph node biopsy (SLNB) helps stage melanoma. Pre-surgical single-photon emission computed tomography/computed tomography (SPECT/CT) visualizes draining lymph nodes, but intraoperative gamma probe detection only estimates SLN location. This study evaluates augmented reality (AR) for projecting pre-surgical SLN imaging onto patients to aid precise localization and extraction.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Molecular sieves (8 mm) incubated in fluorine-18 simulated lymph nodes and were implanted in the head and neck region of cadavers. Positron emission tomography/magnetic resonance imaging (PET/MRI) replaced SPECT/CT due to institutional restriction on cadavers. Virtual PET/MRI renderings were projected using the HoloLens 2 and custom software. Five cadavers underwent surgeries with standard, AR, and AR with head movement compensation methods.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>AR achieved a mean surface localization error of 2.5±2.0 mm (range, 0–8 mm) and a depth error of 2.3±1.7 mm (range, 1–7 mm), both within PET voxel resolution. For more challenging level V nodes, the mean surface error slightly increased to 2.9 mm. Compared to manual surface marking, which had an average error of 18.6±13.0 mm (range, 6–62 mm), the AR system significantly reduced errors both in the head-straight and rotated positions (<i>p</i> &lt;.001). Additionally, the AR system reduced the task completion time by 74% (35.1/47.4 s), with an average time of 12.3 s compared to 47.4 s for manual methods.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>The AR system demonstrated high accuracy and efficiency in SLN localization, integrating head-movement compensation and 3D visualization to improve precision and reduce operating room time.</p><h3 data-test=\"abstract-sub-heading\">Clinical trial number</h3><p>Not applicable.</p><h3 data-test=\"abstract-sub-heading\">Graphic abstract</h3>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"183 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143677648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistent somatostatin PET signs of inflammatory cells 4 to 5 months after acute myocarditis are linked to a poorer recovery of cardiac function","authors":"Thomas Larive, Caroline Boursier, Marine Claudin, Jeanne Varlot, Laura Filippetti, Olivier Huttin, Véronique Roch, Laetitia Imbert, Matthieu Doyen, Antoine Fraix, Damien Mandry, Elodie Chevalier, Pierre-Yves Marie","doi":"10.1007/s00259-025-07202-5","DOIUrl":"https://doi.org/10.1007/s00259-025-07202-5","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Acute Myocarditis (AM) was recently shown to be detected by the Somatostatin Positron Emission Tomography (PET) criterion of &gt; 18 cm³ Myocardial Uptake Volume (MUV), a sign of significant inflammatory cell infiltration. This study characterizes patients for whom this criterion persists 4 to 5 months after AM.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Cardiac Magnetic Resonance (CMR) and [⁶⁸ Ga]Ga-DOTA-TOC PET data from 27 AM patients (2 women, median age 26.5 years [interquartile range: 21.9–31.9]) were analyzed at the acute phase and at a 4.5 [4.3–5.0] month follow-up.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Eleven AM patients (41%) still had &gt; 18 cm³ MUV at the follow-up (PET +). The left ventricular ejection fraction (LVEF) was correlated with MUV at baseline (<i>p</i> = 0.011) and follow-up (<i>p</i> = 0.001) and was lower at follow-up in PET + (52.9 [48.6; 55.0] %) than in the other patients (56.0 [54.3; 57.8] %, <i>p</i> = 0.001). However, this poorer recovery of the PET + LVEF was associated with two MUV evolution profiles evocative of different mechanisms: (i) a prolonged active disease in the 5 PET + patients for whom the MUV increased at follow-up, in association with a slight decrease in LVEF (p = 0.08), and (ii) a more severe initial insult in the 6 other PET + patients for whom the MUV decreased at follow-up with concomitant increases in LVEF (<i>p</i> = 0.028) but these improvements started from much worse baseline LVEF and MUV (respectively, <i>p</i> = 0.022 and 0.003 vs. the other patients).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Somatostatin PET monitoring of AM unveils numerous patients with signs of a persistent inflammatory cell infiltrate 4 to 5 months after acute myocarditis. This persistence is associated with poorer recovery of cardiac function and is seemingly due to active inflammation that is either more severe at baseline or continues to expand over the following months.</p><p><b>Trial registration number:</b> NCT03347760 on clinicaltrials.gov. </p><p><b>Registration date:</b> 22–11-2017.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"70 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143672736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intriguing combination of hepatic metastatic GIST and neuroendocrine tumor in the same patient: Disease monitoring and treatment guidance through dual tracer PET/CT and biopsy","authors":"Austin Saju, Rahul V. Parghane, Sandip Basu","doi":"10.1007/s00259-025-07207-0","DOIUrl":"https://doi.org/10.1007/s00259-025-07207-0","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"56 7 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143672758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synthetic imaging for research and education in nuclear medicine: Who's afraid of the black box?","authors":"Luca Urso, Luigi Manco, Luca Filippi","doi":"10.1007/s00259-025-07214-1","DOIUrl":"https://doi.org/10.1007/s00259-025-07214-1","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143676616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}